McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328–2337 (2017).
Scherer, H. U., Huizinga, T. W. J., Krönke, G., Schett, G. & Toes, R. E. M. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat. Rev. Rheumatol. 14, 157–169 (2018).
Elliott, S. E. et al. B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF-α production. Clin. Immunol. 212, 108360 (2020).
Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581 (2004).
Stohl, W. et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann. Rheum. Dis. 71, 1289–1296 (2012).
Taylor, P. C. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119–2125 (2011).
Tascilar, K. et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol 3, e767–e777 (2021).
Pollastro, S. et al. Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann. Rheum. Dis. 78, 1339–1345 (2019).
Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheumatic Dis. 84, 2065–2074 (2025).
Neppelenbroek, S. et al. Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis. J. Autoimmun. 149, 103320 (2024).
Boeters, D. M., Burgers, L. E., Toes, R. E. M. & van der Helm-van Mil, A. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status. Ann. Rheumatic Dis. 78, 1497–1504 (2019).
Avouac, J. et al. Roads and detours for CAR T cell therapy in autoimmune diseases. Nat. Rev. Drug Discov. 25, 290–309 (2026).
Schett, G. & Xu, H. Resetting autoimmune disease with CAR cell therapies. Nat. Med. 32, 2007–2016 (2026).
Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).
Müller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nat. Med. 32, 1142–1151 (2026).
Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
Becilli, M. et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nat. Med. 32, 1105–1117 (2026).
Szabo, D. et al. Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10, e004727 (2024).
Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597–1598 (2024).
Li, Y. et al. Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. 34, 220–223 (2025).
Lidar, M. et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann. Rheum. Dis. 84, 370–372 (2025).
Albach, F. N. et al. Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology 64, 4075–4077 (2025).
Albach, R. N. et al. Rapid and profound treatment response of difficult-to-treat rheumatoid arthritis to CD19 CAR T-cell therapy. EULAR Rheumatol. Open 2, 100053 (2025).
Caricchio, R. et al. A guide for initiating and managing chimeric antigen receptor T cell therapy clinical trials in autoimmune rheumatic diseases. ACR Open Rheumatol. 7, e70139 (2025).
Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine 69, 102476 (2024).
Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978–3992 (2021).
Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959–3964 (2008).
Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295–1306 (2020).
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).
Lu, L., Xie, M., Yang, B., Zhao, W. B. & Cao, J. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci. Adv. 10, eadj6251 (2024).
Manzo, A. et al. Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study. RMD Open 11, e005079 (2025).
Bécède, M. et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin. Arthritis Rheum. 49, 211–217 (2019).
Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146–2154 (2003).
Wunderlich, C., Oliviera, I., Figueiredo, C. P., Rech, J. & Schett, G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis. Semin. Arthritis Rheum. 46, 709–714 (2017).
Ramwadhdoebe, T. H. et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology 58, 1075–1085 (2019).
Rehnberg, M., Amu, S., Tarkowski, A., Bokarewa, M. I. & Brisslert, M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11, R123 (2009).
Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593–1601 (2024).
Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19−CD38hiCD138+ subset in human bone marrow. Immunity 43, 132–145 (2015).
Bucci, L. et al. BCMA T-cell engager therapy in patients with refractory autoimmune disease. N. Engl. J. Med. 393, 1544–1547 (2025).
Düsing, C. et al. Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat. Med. 32, 1530–1542 (2026).
Feng, J. et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3725–3736 (2025).
Moon, J. S. et al. Cytotoxic CD8. Nat. Commun. 14, 319 (2023).
Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).
Nygaard, G. & Firestein, G. S. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol. 16, 316–333 (2020).
Taylor, P. C. Pain in the joints and beyond; the challenge of rheumatoid arthritis. Lancet Rheumatol. 5, e351–e360 (2023).
Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? Rheumatology 64, 65–73 (2025).
Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).
Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270–280 (2020).
Mougiakakos, D. et al. Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. Cytotherapy 27, 236–246 (2025).
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
Wells, G. et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954–960 (2009).
Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995).
Cella, D. et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J. Rheumatol. 32, 811–819 (2005).
Seror, R., Tubach, F., Baron, G., Guillemin, F. & Ravaud, P. Measure of function in rheumatoid arthritis: individualised or classical scales? Ann. Rheum. Dis. 69, 97–101 (2010).
Matcham, F. et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin. Arthritis Rheum. 44, 123–130 (2014).
D’Agostino, M. A. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce. RMD Open 3, e000428 (2017).
Reijm, S. et al. Autoreactive B cells in rheumatoid arthritis include mainly activated CXCR3+ memory B cells and plasmablasts. JCI Insight 8, e172006 (2023).
Van Gassen, S., Gaudilliere, B., Angst, M. S., Saeys, Y. & Aghaeepour, N. CytoNorm: a normalization algorithm for cytometry data. Cytometry A 97, 268–278 (2020).
Falck, D. & Wuhrer, M. GlYcoLISA: antigen-specific and subclass-specific IgG Fc glycosylation analysis based on an immunosorbent assay with an LC-MS readout. Nat. Protoc. 19, 1887–1909 (2024).
Gijze, S. et al. Simultaneous protein quantitation and glycosylation profiling of antigen-specific immunoglobulin G1 in large clinical studies. J. Proteome Res. 23, 5600–5605 (2024).
Vogl, T. et al. Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota. Nat. Med. 27, 1442–1450 (2021).
Xu, G. J. et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348, aaa0698 (2015).
Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 39, e102 (2011).
